Hu Yang, Ph.D. profile photo

Hu Yang, Ph.D.

Qimonda Professor, Department of Chemical and Life Science Engineering

hyang2@vcu.edu, 804-828-5459, Biotech 8, Room 418, 737 North 5th, Richmond, VA, UNITED STATES

hyang2@vcu.edu

Dr. Yang's research is at the convergence of materials science and translational medicine.

Social

Biography

Grant reviewer for NIH and NSF;
Editorial Board, Journal of Biological Engineering;
Editorial Board, International Journal of Polymeric Materials and Polymeric Biomaterials

Industry Expertise

  • Research
  • Education/Learning
  • Chemicals
  • Nanotechnology
  • Pharmaceuticals

Areas of Expertise

atherosclerosisGlaucomaNano-BiotechnologyClick chemistryBioorthogonal chemistryCentral nervous system trauma and diseasesHead and Neck CancersOcular BiomaterialsTranslational ResearchSmart polymeric materials and structuresNanoscience and nanotechnologyNanoparticlesGene TherapyDrug DeliveryDendrimerCancer ResearchTissue EngineeringBiomaterialsPolymer Characterization and ProcessingTranslational Medicine

Accomplishments

Qimonda Professorship | professional

Awarded by Qimonda.

NSF Career Award | professional

Awarded by the National Science Foundation.

Wallace Coulter Foundation Translational Research Award | professional

Awarded by the Wallace H. Coulter Foundation.

Education

University of Wisconsin-Madison

Postdoc, Pharmaceutical Sciences

2005

University of Akron

Ph.D., Chemical Engineering

2004

Sichuan University

B.E., Polymer

1998

Affiliations

  • Department of Chemical and Life Science Engineering (primary)
  • Department of Pharmaceutics (joint)
  • Department of Biomedical Engineering (affiliate)
  • Massey Cancer Center
  • Society for Biomaterials

Patents

Clickable polyoxetane carrier for drug delivery

US9421276

2016-08-23

view more

Selected Articles

Leutusome: A biomimetic nanoplatform integrating plasma membrane components of leukocytes and tumor cells for remarkably enhanced solid tumor homing | Nano Letters

Cell membrane-camouflaged nanoparticles have appeared as a promising platform to develop active tumor targeting nanomedicines. To evade the immune surveillance, we designed a composite cell membrane-camouflaged biomimetic nanoplatform, namely, leutusome, which is made of liposomal nanoparticles incorporating plasma membrane components derived from both leukocytes (murine J774A.1 cells) and tumor cells (head and neck tumor cells HN12). Exogenous phospholipids were used as building blocks to fuse with two cell membranes to form liposomal nanoparticles. Liposomal nanoparticles made of exogenous phospholipids only or in combination with one type of cell membrane were fabricated and compared. The anticancer drug paclitaxel (PTX) was used to make drug-encapsulating liposomal nanoparticles. Leutusome resembling characteristic plasma membrane components of the two cell membranes were examined and confirmed in vitro. A xenograft mouse model of head and neck cancer was used to profile the blood clearance kinetics, biodistribution, and antitumor efficacy of the different liposomal nanoparticles. The results demonstrated that leutusome obtained prolonged blood circulation and was most efficient accumulating at the tumor site (79.1 ± 6.6% ID per gram of tumor). Similarly, leutusome composed of membrane fractions of B16 melanoma cells and leukocytes (J774A.1) showed prominent accumulation within the B16 tumor, suggesting the generalization of the approach. Furthermore, PTX-encapsulating leutusome was found to most potently inhibit tumor growth while not causing systemic adverse effects.

view more
Folic Acid-Decorated Polyamidoamine Dendrimer Exhibits High Tumor Uptake and Sustained Highly Localized Retention in Solid Tumors: Its Utility for Local siRNA Delivery | Acta Biomater.

The utility of folic acid (FA)-decorated polyamidoamine dendrimer G4 (G4-FA) as a vector was investigated for local delivery of siRNA. In a xenograft HN12 (or HN12-YFP) tumor mouse model of head and neck squamous cell carcinomas (HNSCC), intratumorally (i.t.) injected G4-FA exhibited high tumor uptake and sustained highly localized retention in the tumors according to near infrared (NIR) imaging assessment. siRNA against vascular endothelial growth factor A (siVEGFA) was chosen as a therapeutic modality. Compared to the nontherapeutic treatment groups (PBS solution or dendrimer complexed with nontherapeutic green fluorescent protein siRNA [siGFP]), G4-FA/siVEGFA showed tumor inhibition effects in single-dose and two-dose regimen studies. In particular, two doses of G4-FA/siVEGFA i.t. administered eight days apart resulted in a more profound inhibition of tumor growth, accompanied with significant reduction in angiogenesis, as judged by CD31 staining and microvessel counts. Tumor size reduction in the two-dose regimen study was ascertained semi-quantitatively by live fluorescence imaging of YFP tumors and independently supported antitumor effects of G4-FA/siVEGFA. Taken together, G4-FA shows high tumor uptake and sustained retention properties, making i

view more
Targeted nanosystems: Advances in targeted dendrimers for cancer therapy, | Nanomedicine: Nanotechnology, Biology and Medicine

2016

Dendrimers possess discrete highly compact nanostructures constituted of successive branched layers. Soon after the inception of dendrimers, recognition of their tunable structures and biologically favorable properties provoked a great enthusiasm in delving deeply into the utility of dendrimers for biomedical and pharmaceutical applications. One of the most important nanotechnology applications is the development of nanomedicines for targeted cancer therapies. Tremendous success in targeted therapies has been achieved with the use of dendrimer-based nanomedicines. This article provides a concise review on latest advances in the utility of dendrimers in immunotherapies and hormone therapies.

view more